Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03097380 | PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium | PHASE1 | COMPLETED | 19 | — | — | Apr 26, 2017 | Dec 30, 2017 | Aug 30, 2021 | 1 | Sweden |
To describe the AZD2115 dose-muscarinic receptor occupancy relationship in the lungs in healthy volunteers
| Arm | Type | Description |
|---|---|---|
| AZD2115 | EXPERIMENTAL | - |
| Spiriva (Tiotropium) | ACTIVE_COMPARATOR | - |
| [11C]AZ13754366 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AZD2115 | DRUG | AZD2115 |
| SPIRIVA | DRUG | Tiotropium |
| [11C]AZ13754366 | RADIATION | Radioligand |
Inclusion Criteria: * Provision of signed and dated written informed consent prior to any study specific procedures * Healthy male subjects, aged 20 to 50 years (inclusive) * Male subjects must be surgically sterile or use an acceptable method of contraception (defined as barrier methods in conjunc...